A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Status:
Not yet recruiting
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
The reason for this study is to collect safety and efficacy information regarding the study
drug remternetug in participants with early Alzheimer's disease (AD).